Moderna's successful vaccine sale does not appear to be a one-off and the potential it can offer personalized cancer vaccines now that the company is a household name without a single advertisement in my view speaks volumes of how it may become the preferred treatment for successful cancer vaccines. Also, it will increase the reason for a buyout or acquisition which either of the two scenarios will be very expensive, especially if the shares are trading at a much higher valuation than the share sells for today.
It may be riskier not to own Moderna into its upcoming earnings and what follows than not. Despite some comments otherwise, I am of the view Moderna is far from going up with a very high multiple and an unexpected variable target price which will result in the companies valuation above Merck & Co., Inc. and Pfizers. David does continue to appear will become more valuable than the current Goliaths. I am of the view the Co-Founder & CEO & Director are up to the task to make it happen much sooner than some may expect.
Comments